첫 페이지 News 본문

Merck announced that its PD-1 inhibitor pembrolizumab (trade name: pembrolizumab) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of locally advanced cervical cancer in China. It is used in combination with radiotherapy and chemotherapy for the treatment of stage III-IVA cervical cancer patients in the International Federation of Obstetrics and Gynecology (FIGO) 2014. The approval of this new indication is based on data from the global phase III clinical trial KEYNOTE-A18.
您需要登录后才可以回帖 登录 | Sign Up

本版积分规则

本兮我爱你 新手上路
  • Follow

    0

  • Following

    0

  • Articles

    2